Literature DB >> 15893124

Unifying mechanism for addiction and toxicity of abused drugs with application to dopamine and glutamate mediators: electron transfer and reactive oxygen species.

Peter Kovacic1.   

Abstract

There are many unknown aspects concerning the mode of action of abused drugs. Recently, a unifying theme for toxicity and addiction was reported based on electron transfer (ET), reactive oxygen species (ROS), and oxidative stress (OS). The main drugs involved are nicotine, cocaine, alcohol, phencyclidine, ecstasy, amphetamines, morphine-heroin, tetrahydrocannabinol, and therapeutic drugs (benzodiazepines, phenytoin, phenobarbital, aspirin, and acetaminophen). A major source of ROS is ET functionalities, of which the main ones found in abused drug metabolites are quinones and imines (or iminiums). Minor types are the nitroxide metabolite from cocaine, and alpha-dicarbonyl from alcohol. The theoretical approach enjoys support from reports on formation of ET metabolites, generation of ROS, protection by antioxidants (AOs), electrochemical studies, and cell signaling. Dopamine (DA) mediation of drug abuse has been the focus of much attention during the past decades. Recently, a similar role for glutamate (Glu) has come under study. Superficially, from a mechanistic vantage point, these findings might be regarded as in conflict with the ET-ROS-OS scheme. Many investigators believe that each drug or mediator operates by its own distinct mechanism. The present report provides evidence that a commonality in mode of action exists for both abused drugs and the DA-Glu operators. In the case of DA, oxidative metabolism yields o-quinones and semiquinones which can redox cycle with oxygen to provide various ROS. Electrochemical studies support the possibility of ET transformations by these quinones in the biological domain. In relation to cell signaling, DA is involved in formation of cAMP followed by a cascade of other events. A similar scenario exists in the case of Glu, in which an iminocarboxylic acid metabolite is hypothesized to play an ET role. The various phenomena are rationalized within the context of ET-ROS-OS, as was done earlier for abused drugs. Thus, a common mode of action may exist for both categories since all provide metabolites with similar properties. Stimulation of mediator production by abused drugs can occur with subsequent oxidation by ROS, some of which may be supplied by the drugs. In addition to prevention, the difficult topic of addiction mechanism is addressed from the viewpoint of ET and ROS involvement. Low levels of ROS would pertain since high concentrations are related to toxicity. A report that tetrahydrocannabinol does not comprise a substantial risk is in accord with little evidence of OS and absence of ET functionalities in the drug and reported metabolites.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15893124     DOI: 10.1016/j.mehy.2005.01.031

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  20 in total

Review 1.  Smoking and increased Alzheimer's disease risk: a review of potential mechanisms.

Authors:  Timothy C Durazzo; Niklas Mattsson; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2014-06       Impact factor: 21.566

2.  Interactive effects of chronic cigarette smoking and age on hippocampal volumes.

Authors:  Timothy C Durazzo; Dieter J Meyerhoff; Sara Jo Nixon
Journal:  Drug Alcohol Depend       Date:  2013-09-02       Impact factor: 4.492

3.  Cellular and molecular oxidative stress-related effects in uterine myometrial and trophoblast-decidual tissues after perigestational alcohol intake up to early mouse organogenesis.

Authors:  Tamara Anahí Coll; Gabriela Chaufan; Leticia Gabriela Pérez-Tito; Martín Ricardo Ventureira; María Del Carmen Ríos de Molina; Elisa Cebral
Journal:  Mol Cell Biochem       Date:  2017-08-18       Impact factor: 3.396

4.  Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline.

Authors:  Wei Sha; Kerry-Ann da Costa; Leslie M Fischer; Michael V Milburn; Kay A Lawton; Alvin Berger; Wei Jia; Steven H Zeisel
Journal:  FASEB J       Date:  2010-04-06       Impact factor: 5.191

5.  Oxidative stress and BDNF as possible markers for the severity of crack cocaine use in early withdrawal.

Authors:  Anne Orgle Sordi; Flavio Pechansky; Felix Henrique Paim Kessler; Flávio Kapczinski; Bianca Pfaffenseller; Carolina Gubert; Bianca Wollenhaupt de Aguiar; Joana Correa de Magalhães Narvaez; Felipe Ornell; Lisia von Diemen
Journal:  Psychopharmacology (Berl)       Date:  2014-03-28       Impact factor: 4.530

6.  Cerebellar Morphometry and Cognition in the Context of Chronic Alcohol Consumption and Cigarette Smoking.

Authors:  Valerie A Cardenas; Christina M Hough; Timothy C Durazzo; Dieter J Meyerhoff
Journal:  Alcohol Clin Exp Res       Date:  2019-11-15       Impact factor: 3.455

7.  The structure of dopamine induced alpha-synuclein oligomers.

Authors:  Agata Rekas; Robert B Knott; Anna Sokolova; Kevin J Barnham; Keyla A Perez; Colin L Masters; Simon C Drew; Roberto Cappai; Cyril C Curtain; Chi L L Pham
Journal:  Eur Biophys J       Date:  2010-03-23       Impact factor: 1.733

Review 8.  r

Authors:  Jacqueline S Womersley; Danyelle M Townsend; Peter W Kalivas; Joachim D Uys
Journal:  Eur J Neurosci       Date:  2018-09-24       Impact factor: 3.386

9.  History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress.

Authors:  Timothy C Durazzo; Niklas Mattsson; Michael W Weiner; Magdalena Korecka; John Q Trojanowski; Leslie M Shaw
Journal:  Drug Alcohol Depend       Date:  2014-07-03       Impact factor: 4.492

10.  Involvement of reactive oxygen species in cocaine-taking behaviors in rats.

Authors:  Eun Young Jang; Yeon-Hee Ryu; Bong Hyo Lee; Su-Chan Chang; Mi Jin Yeo; Sang Hyun Kim; Ryan J Folsom; Nathan D Schilaty; Kwang Joong Kim; Chae Ha Yang; Scott C Steffensen; Hee Young Kim
Journal:  Addict Biol       Date:  2014-06-26       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.